A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers

GSK598809 is being developed to facilitate overcoming an addiction to nicotine and to help people stop smoking. This study will investigate if GSK598809 is safe and tolerated in people who smoke and will also look at blood levels of GSK598809 and nicotine.

Inclusion criteria:

• Healthy adult male smoker between the ages of 18 and 50 years
• Body weight greater than 50kg and BMI between 18.5-29.9 kg/m2.
• No abnormalities on the medical, psychiatric or laboratory evaluation
• Smoke on average more than 20 but less that 40 cigarettes per day for the past year and not tried to give up in the 3 months before the study.

Exclusion criteria:

• History of psychiatric disorder or sleep disorder.
• Receiving treatment for smoking cessation.
• Use tobacco products other than cigarettes.